Androgen Deprivation Therapy News and Research

RSS
New risk classification system proposed for prostate cancer

New risk classification system proposed for prostate cancer

Study: microRNA is designed to stop proliferation of prostate cancer cells

Study: microRNA is designed to stop proliferation of prostate cancer cells

Researchers study effectiveness of intermittent therapy for prostate cancer treatment

Researchers study effectiveness of intermittent therapy for prostate cancer treatment

Prostate tissue androgen content predicts ADT outcome

Prostate tissue androgen content predicts ADT outcome

Androgen deprivation therapy interferes with diabetes control

Androgen deprivation therapy interferes with diabetes control

GCP could help lengthen life expectancy of certain prostate cancer patients

GCP could help lengthen life expectancy of certain prostate cancer patients

ADT increases risk of fracture incidence after treatment completion in men with prostate cancer

ADT increases risk of fracture incidence after treatment completion in men with prostate cancer

Penis shrinkage caution for prostate cancer patients

Penis shrinkage caution for prostate cancer patients

Perceived reduction in penis size linked to regrets of prostate cancer treatment choice

Perceived reduction in penis size linked to regrets of prostate cancer treatment choice

Active surveillance of prostate cancer patients encouraged

Active surveillance of prostate cancer patients encouraged

Androgen deprivation therapies may have adverse effects in men with precancers

Androgen deprivation therapies may have adverse effects in men with precancers

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Study identifies genetic variations as predictors of prostate cancer-related fatigue

Study identifies genetic variations as predictors of prostate cancer-related fatigue

September issue of JNCCN publishes two prostate cancer articles

September issue of JNCCN publishes two prostate cancer articles

Alendronate decreases BMD loss in prostate cancer

Alendronate decreases BMD loss in prostate cancer

Intermittent hormone therapy effective for prostate cancer patients

Intermittent hormone therapy effective for prostate cancer patients

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Enzalutamide drug extends survival in people with advanced prostate cancer

Enzalutamide drug extends survival in people with advanced prostate cancer

Therapeutic breaks for prostate cancer patients

Therapeutic breaks for prostate cancer patients

High BMI linked to poor outcomes after prostatectomy and ADT

High BMI linked to poor outcomes after prostatectomy and ADT